Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.
PAION grants exclusive license to Mundipharma for development and commercialization of remimazolam in Japan
FDA considers current human abuse liability program with Remimazolam in the U.S. as sufficient; no second intranasal study required
PAION AG raises EUR 8.0 million in private placement
PAION reports positive headline data in U.S. Phase III trial with remimazolam for procedural sedation during bronchoscopy
PAION successfully completes patient recruitment in U.S. Phase III study with remimazolam for procedural sedation during bronchoscopy
PAION reports positive headline data in U.S. clinical safety trial of remimazolam in high-risk patients undergoing colonoscopy
PAION AG to issue approx 2.4 Million Shares at EUR 2.05 per share in capital increase with subscription rights